Back to all studies
RecruitingNCT06634641

Clozapine-related Immunodeficiency in Parkinsons Disease

This study is recruiting. It focuses on schizophrenia and currently lists participation information in France.

Schizophrenia, Clozapine, ...BiologicalOver 18 Years
Need help deciding?

Ask HopeStage to review this study with me

Loading the security check...
Study ID: NCT06634641. We help you review the study, but cannot decide medical eligibility.
In plain English

Key information made simple

What is this study testing?

This study is testing whether the study approach may be useful for adults experiencing schizophrenia.

What would participation involve?

Participants may complete study activities around the study approach, complete questionnaires or follow-up assessments, attend study visits with the research team. The registry lists locations in France.

Who is it mainly for?

This study appears to be mainly for adults with schizophrenia.

What should you check before joining?

Ask about whether there is a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.

What to expect

Your next step

The official record suggests in-person participation through a research setting, with sites including CHU Amiens-Picardie in Salouël. Participation appears to involve assessments along with scans or samples to help researchers understand patterns more clearly. The main fit is usually being able to follow the planned visits or tasks and being able to understand the study and consent, while common reasons not to take part include active substance or alcohol problems that could affect the results. This is a later-stage study, which usually means the approach is being followed in broader real-world use.

Before joining

Questions to ask before joining

Study clarity

Things to check before joining

Study start dateStarted: October 1, 2024
Recruitment status
Recruiting
Estimated enrollment
Not clearly listed
Sponsor
Centre Hospitalier Universitaire, Amiens
Sponsor type
Unknown or unclear
Study type
Biological
Intervention type
Biological / biomarker / imaging
Study phase
Not clearly listed
Locations
France
Age range
Over 18 Years
Official registry ID
NCT06634641
Official title
Clozapine-related Immunodeficiency in Parkinsons Disease
Official source
Official registry link

Want help reviewing this study?

Loading the security check...
Study ID: NCT06634641. We help you review the study, but cannot decide medical eligibility.
In practice

For you

Taking part may give access to a new approach being evaluated.

It requires regular visits and structured follow-up.

Requires travel, with in-person participation in France.

Important

Not medical advice

Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com

FAQ

Questions about this study

What is this study trying to understand?

This study is exploring observational follow-up for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.

Does this study involve biological samples, imaging, or biomarkers?

This appears to be a biological / biomarker / imaging study. The phase is not clearly listed in the public registry. Phase is mostly relevant for medication studies and some device studies. For this study, it may be more useful to look at what is required, the duration, visits, and eligibility criteria.

Do I need to want to stop or reduce tobacco use to participate?

The public registry appears to mention tobacco, nicotine, alcohol, cannabis, or another addiction-related topic. Ask the study team whether you need to want to stop, reduce, already be abstinent, or simply meet use-related criteria. Eligibility must be confirmed by the study team.

What would I likely need to do?

You may need to provide biological samples, complete lab tests, or take part in imaging or measurement procedures. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.

What should I check about samples, imaging, data, and possible discomfort?

If the study involves samples, imaging, or biomarkers, ask what is collected, how it is stored, who can access results, whether there may be discomfort, and whether results are shared with you. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.

Will I need to travel or attend in-person visits?

The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.

Who is behind this study?

This study is sponsored by Centre Hospitalier Universitaire, Amiens, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.

Can I still join this study?

The registry indicates that this study is currently recruiting. This does not mean you are eligible: the study team must confirm the criteria, available locations, and next steps.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me